



Daiichi-Sankyo

# Reference Data

## (3Q of FY2006)

1 Summary of Financial Statement	1
2 Currency Exchange rate	1
3 Status of R&D Pipeline	1
(Change from the announcement of November 2006)	
4 Global Product Sales	2
5 Overseas Sales	2
6 Information by Operating Segment	3
7 Information by Geographic Segment	3,4
8 Domestic Sales	5
9 Sales of Overseas Subsidiaries	6

January 31, 2007

Corporate Communications Department  
[http:// www.daiichisankyo. com](http://www.daiichisankyo.com)

## 1.Summary of Financial Statement

million yen

	FY2005		FY2006										
	1-3Q	Full Year	1st half		3Q	1-3Q		2nd half (New Estimate)			Full Year (New Estimate)		
			Pharmaceutical s business* Total			Pharmaceutical s business* Total		Difference from Estimate in November	Pharmaceutical s business* Total		Difference from Estimate in November	Pharmaceutical s business* Total	
Change		<1.0>	<7.5>		<-2.9>	<3.8>		<-7.4>			<-0.1>		
Net sales	704,039	925,918	485,842	433,502	244,805	730,647	663,257	439,158	7,000	402,498	925,000	7,000	836,000
Cost of sales	219,728	290,735	138,022	104,580	70,339	208,361	163,311	124,478	-2,500	97,420	262,500	-2,500	202,000
Cost of sales ratio	31.2%	31.4%	28.4%	24.1%	28.7%	28.5%	24.6%	28.3%		24.2%	28.4%		24.2%
Selling, general and administrative expenses	350,016	480,454	269,466	252,792	120,822	390,288	370,706	255,034	-1,500	248,208	524,500	-1,500	501,000
SG&A ratio	49.7%	51.9%	55.5%	58.3%	49.4%	53.4%	55.9%	58.1%		61.7%	56.7%		59.9%
Research and development expenses	113,371	158,716	84,939	81,655	40,389	125,328	121,359	84,061	-1,000	82,345	169,000	-1,000	164,000
R&D ratio	16.1%	17.1%	17.5%	18.8%	16.5%	17.2%	18.3%	19.1%		20.5%	18.3%		19.6%
Change		<9.7>	<-2.5>		<-0.6>	<-1.7>		<-19.8>			<-10.8>		
Operating income	134,294	154,728	78,353	76,130	53,644	131,997	129,240	59,647	11,000	56,870	138,000	11,000	133,000
/ Net sales	19.1%	16.7%	16.1%	17.6%	21.9%	18.1%	19.5%	13.6%		14.1%	14.9%		15.9%
Change		<14.2>	<6.7>		<3.0>	<5.2>		<-17.2>			<-4.8>		
Ordinary income	138,890	159,714	88,208	—	57,913	146,121	—	63,792	12,000	—	152,000	12,000	—
/ Net sales	19.7%	17.2%	18.2%	—	23.7%	20.0%	—	14.5%		—	16.4%		—
Change		<2.6>	<35.3>		<-65.7>	<-4.1>		<-89.2>			<-19.0>		
Net income	80,992	87,692	66,886	—	10,807	77,693	—	4,114	8,000	—	71,000	8,000	—
/ Net sales	11.5%	9.5%	13.8%	—	4.4%	10.6%	—	0.9%		—	7.7%		—

\*Continuing business

### Notes

• The accounting period of DAIICHSANKYO INC. (DSI) and Luitpold Pharmaceuticals Inc. (LPI), both of which are overseas subsidiaries of the DAIICHI SANKYO Group, is 15 months from January 2006 to March 2007. This is due to an adjustment made to the accounting period.

• In fiscal 2006, Zepharm Inc., Taiwan Sankyo Ltd. And Shanghai Sankyo Pharmaceuticals Ltd., were made consolidated subsidiaries of DAIICHI SANKYO CO., LTD. In the case of the share acquisition of Zepharm Inc., intangible assets and goodwill be amortized over a period of 10 years.

## 2.Exchange rate

	FY2005		FY2006		
	1-3Q	Full Year	1st half	1-3Q	Full Year
Yen/\$ (Average)	—	—	115.9	116.4	116
Yen/EUR (Average)	—	—	European subsidiaries:142.2* Exports: 146*	European subsidiaries:144.2* Exports: 149.7*	146

\*due to difference of accounting term

## 3.Status in R&D Pipeline (Change from the announcement of November 2006)

### Development Stage

Development Code Number	Before Change	After Change	Remarks
CS-747	Japan:P-1	Japan:P-2	anti-platelet agent
CS-8663	US:P-3	US: Application	antihypertensive drug (olmesartan/amlodipine combination)
WeiChol DM	US:P-3	US: Application	additional indication for diabetes of WeiChol
DF-098	Japan:Application	Japan:Approval	<i>Haemophilus influenzae</i> type b conjugate vaccine
DL-404	Japan:Application	Japan:Approval	additional pediatric indication of Intrathecal Gabalon

#### 4.Consolidated sales of Global Products

million yen

	FY2005			FY2006										
	1-3Q	Full Year		1st half	3Q			2nd half New Estimate		1-3Q		Full Year New Estimate		
		Change VS 2004			Change VS 2005	Progress		Difference from estimate	Change VS 2005		Change VS 2005			
Olmesartan* [antihypertensive]	67,300	92,400	102.6%	84,000	104.4%	39,700	51.5%	51.4%	<b>77,300</b>	3,600	<b>123,700</b>	83.8%	<b>161,300</b>	74.6%
Japan : Olmetec	18,900	25,600	184.4%	19,400	94.0%	13,600	52.8%	56.2%	<b>24,200</b>	0	<b>33,000</b>	74.6%	<b>43,600</b>	70.3%
U.S.A: Benicar	36,200	50,300	66.0%	53,300	133.8%	19,700	47.0%	50.1%	<b>39,300</b>	3,200	<b>73,000</b>	101.7%	<b>92,600</b>	84.1%
Europe: Olmetec	10,700	14,700	153.4%	10,100	40.3%	5,700	62.9%	46.0%	<b>12,400</b>	0	<b>15,800</b>	47.7%	<b>22,500</b>	53.1%
Others	1,500	1,800	260.0%	1,200	9.1%	700	75.0%	50.0%	<b>1,400</b>	600	<b>1,900</b>	26.7%	<b>2,600</b>	44.4%
Levofloxacin [oral antibacterials]	76,200	97,600	8.1%	46,200	-0.9%	30,900	4.4%	58.9%	<b>52,500</b>	1,900	<b>77,100</b>	1.2%	<b>98,700</b>	1.1%
Japan : Cravit	40,200	50,200	6.6%	21,000	-11.0%	17,000	2.4%	63.7%	<b>26,700</b>	700	<b>38,000</b>	-5.5%	<b>47,700</b>	-5.0%
Export:	23,000	29,500	21.9%	16,400	10.1%	8,700	7.4%	54.0%	<b>16,100</b>	1,200	<b>25,100</b>	9.1%	<b>32,500</b>	10.2%
Royalty	13,000	17,900	-5.8%	8,800	8.6%	5,200	6.1%	53.6%	<b>9,700</b>	0	<b>14,000</b>	7.7%	<b>18,500</b>	3.4%
Pravastatin [antihyperlipidemic agent]	117,500	143,200	-14.1%	52,000	-34.3%	24,600	-35.8%	60.7%	<b>40,500</b>	-1,300	<b>76,600</b>	-34.8%	<b>92,500</b>	-35.4%
Japan: Mevalotin	60,700	75,200	-8.8%	34,800	-9.6%	20,000	-9.9%	61.7%	<b>32,400</b>	0	<b>54,800</b>	-9.7%	<b>67,200</b>	-10.6%
Europe	3,800	5,500	-47.1%	3,300	37.5%	1,400	0.0%	56.0%	<b>2,500</b>	0	<b>4,700</b>	23.7%	<b>5,800</b>	5.5%
Export:	53,000	62,500	-15.3%	13,900	-63.7%	3,200	-78.2%	57.1%	<b>5,600</b>	-1,300	<b>17,100</b>	-67.7%	<b>19,500</b>	-68.8%

\*1st half sales of Benicar shows 9 months sales .

#### 5.Overseas sales

million yen

	FY2005		FY2006				
	1-3Q	Full Year	1st half	3Q		1-3Q	
				Change VS 2005		Change VS 2005	
North America	139,706	182,614	134,959	54,088	18.3%	<b>189,047</b>	35.3%
Europe	68,665	98,440	44,581	19,063	-17.9%	<b>63,644</b>	-7.3%
Others*	22,524	26,210	15,096	7,743	-7.1%	<b>22,839</b>	1.4%
Overseas sales	230,896	307,265	194,636	80,894	4.7%	<b>275,530</b>	19.3%
/ Net sales	32.8%	33.2%	40.1%	33.0%	2.4%	<b>37.7%</b>	4.9%

\* China, Korea, Thai, Taiwan, Brazil, Venezuela etc.

The accounting period of DAIICHSANKYO INC. (DSI) and Luitpold Pharmaceuticals Inc. (LPI), both of which are overseas subsidiaries of the DAIICHI SANKYO Group, is 15 months. This is due to an adjustment made to the accounting period.

## 6.Consolidated Segment information - Business

million yen

		FY2005	
		1-3Q	Full year
	Domestic	338,382	431,401
	Overseas	217,795	289,530
	OTC drugs	22,424	27,900
	Pharmaceuticals	605,765	784,666
	Other	98,273	141,251
Consolidated Sales		704,039	925,918
	Pharmaceuticals	131,399	148,114
	Other	2,499	6,146
Consolidated Operating income		134,294	154,728

FY2006				
1st half	3Q		1-3Q	Change VS 2005
		Change VS 2005		
215,236	132,718	2.0%	347,954	2.8%
185,169	77,017	6.2%	262,186	20.4%
24,592	15,145	98.5%	39,737	77.2%
441,381	225,480	2.3%	666,861	10.1%
44,460	19,325	-39.4%	63,785	-35.1%
485,842	244,805	-2.9%	730,647	3.8%
75,894	52,818	-1.7%	128,712	-2.0%
2,251	519	191.6%	2,770	10.8%
78,353	53,644	-0.6%	131,997	-1.7%

The accounting period of DAIICHISANKYO INC. (DSI) and Luitpold Pharmaceuticals Inc. (LPI), both of which are overseas subsidiaries of the DAIICHI SANKYO Group, is 15 months. This is due to an adjustment made to the accounting period.

The sales and profit attained through January to March 2006 was sales of ¥31.5 billion, operating income of ¥9.0 billion.

## 7.Consolidated Segment information - Area

million yen

		FY2005		
		1-3Q	%	Full year
	Japan	579,881	82.4%	752,793
	North America	83,079	11.8%	116,061
	Europe	32,647	4.6%	45,473
	Other	8,430	1.2%	11,589
Consolidated Sales		704,039	100.0%	925,918
	Japan	113,470		130,249
	North America	20,377		25,457
	Europe	-424		-685
	Other	779		863
Consolidated Operating income		134,294		154,728

FY2006							
1st half	3Q		1-3Q	Change VS 2005	Change VS 2005	Change VS 2005	
		Change VS 2005					
341,976	70.4%	187,456	76.6%	-10.2%	529,432	72.5%	-8.7%
108,566	22.3%	40,983	16.7%	39.7%	149,549	20.5%	80.0%
27,318	5.6%	11,875	4.9%	5.1%	39,193	5.4%	20.1%
7,980	1.6%	4,492	1.8%	52.3%	12,472	1.7%	47.9%
485,842	100.0%	244,805	100.0%	-2.9%	730,647	100.0%	3.8%
71,642		43,628		-1.6%	115,270		1.6%
33,880		487		-94.2%	34,367		68.7%
5,428		1,780		18.7%	7,208		—
348		206		-32.9%	554		-28.9%
78,353		53,644		-0.6%	131,997		-1.7%

The accounting period of DAIICHISANKYO INC. (DSI) and Luitpold Pharmaceuticals Inc. (LPI), both of which are overseas subsidiaries of the DAIICHI SANKYO Group, is 15 months. This is due to an adjustment made to the accounting period.

The sales and profit attained through January to March 2006 was sales of ¥31.5 billion, operating income of ¥9.0 billion.

## Reference

million yen

		FY2006						
		1st half	3Q	1-3Q	2nd half		Full year	
					Estimate	Difference from Estimate in November		Estimate
P h a r m a c e u t i c a l s	Domestic (Sankyo, Daiichi Pharmaceuticals non-consolidated)	215,236	132,718	347,954	213,264	2,500	428,500	
	US	Exports	24,298	12,344	36,642	21,202	-1,100	45,500
		DSI*	73,616	27,837	101,453	55,584	4,600	129,200
		LPI*	34,962	13,159	48,121	22,638	1,300	57,600
	Europe	Exports	14,808	5,324	20,132	10,692	900	25,500
		DSE	26,698	11,259	37,957	25,702	1,400	52,400
	DAIICHI SANKYO HEALTHCARE CO., LTD. ZEPHARMA	24,592	15,145	39,737	24,308	-800	48,900	
	Other Company(Total)	19,292	11,969	31,261	29,108	-2,800	48,400	
Other	52,340	15,050	67,390	36,660	1,000	89,000		
Consolidated Sales		485,842	244,805	730,647	439,158	7,000	925,000	

The accounting period of DAIICHSANKYO INC. (DSI) and Luitpold Pharmaceuticals Inc. (LPI), both of which are overseas subsidiaries of the DAIICHI SANKYO Group, is 15 months. This is due to an adjustment made to the accounting period.

The sales and profit attained through January to March 2006 was sales of 31.5 billion yen, operating income of 9.0 billion yen.

## 8.Domestic Sales

### Sales of main ethical pharmaceuticals

million yen

		FY2005			FY2006										
		1-3Q	Full Year	Change VS 2004	1st half		3Q		2nd half New Estimate		1-3Q		Full Year New Estimate		
					Change VS 2005	Progress	Change VS 2005	Progress	Difference from estimate	Change VS 2005	Change VS 2005				
Cardiovascular	Mevalotin (antihyperlipidemic agent)	60,700	75,200	-8.8%	34,800	-9.6%	20,000	-9.9%	61.7%	32,400	0	54,800	-9.7%	67,200	-10.6%
	Panelidine (antiplatelet agent)	23,200	28,300	-1.0%	13,200	-10.2%	7,800	-8.2%	65.0%	12,000	1,900	21,000	-9.5%	25,200	-11.0%
	Artist (long-acting beta-blocker)	14,500	18,200	16.7%	9,600	5.5%	5,800	+7.4%	58.6%	9,900	0	15,400	6.2%	19,500	7.1%
	Sunnhythm (antiarrhythmic agent)	9,500	11,900	7.2%	5,900	-1.7%	3,500	0.0%	59.3%	5,900	0	9,400	-1.1%	11,800	-0.8%
	Aeocol (antihypertensive)	7,500	9,100	-16.5%	4,100	-14.6%	2,300	-14.8%	59.0%	3,900	0	6,400	-14.7%	8,000	-12.1%
	Olmotec (antihypertensive)	18,900	25,600	184.4%	19,400	94.0%	13,600	+52.8%	56.2%	24,200	0	33,000	74.6%	43,600	70.3%
	Coversyl (antihypertensive)	7,000	8,400	-3.4%	3,500	-22.2%	2,000	-20.0%	60.6%	3,300	0	5,500	-21.4%	6,800	-19.0%
	Hanp (agent for the treatment of acute cardiac failure)	6,700	8,600	22.9%	4,200	7.7%	3,000	+7.1%	56.6%	5,300	0	7,200	7.5%	9,500	10.5%
	Calblock (antihypertensive)	4,900	6,400	113.3%	4,100	36.7%	2,800	+47.4%	56.0%	5,000	0	6,900	40.8%	9,100	42.2%
	Livalo (antihyperlipidemic agent)	3,200	4,100	95.2%	2,400	20.0%	1,600	+33.3%	59.3%	2,700	-600	4,000	25.0%	5,100	24.4%
Metabolic	Fastic (antidiabetic agent)	4,300	5,300	-1.9%	2,700	0.0%	1,500	-6.3%	55.6%	2,700	0	4,200	-2.3%	5,400	1.9%
Infection	Cravit (oral antibacterial agent)	40,200	50,200	6.6%	21,000	-11.0%	17,000	+2.4%	63.7%	26,700	700	38,000	-5.5%	47,700	-5.0%
	Carbenin (antibiotic)	5,300	6,300	-19.2%	2,700	-20.6%	1,500	-21.1%	65.2%	2,300	0	4,200	-20.8%	5,000	-20.6%
	Banan (antibiotic)	3,500	4,400	-21.4%	1,900	-5.0%	1,200	-20.0%	50.0%	2,400	0	3,100	-11.4%	4,300	-2.3%
Cancer	Topotecin (anti cancer agent)	3,900	4,800	23.1%	2,600	4.0%	1,700	+21.4%	65.4%	2,600	0	4,300	10.3%	5,200	8.3%
Immunity Allergic	Zyrtec (allergy drug)	9,100	12,600	10.5%	5,100	-8.9%	3,300	-5.7%	50.0%	6,600	0	8,400	-7.7%	11,700	-7.1%
Bone/Joint	Loxonin (non-steroidal analgesic and anti-inflammatory agent)	22,700	29,000	1.4%	15,100	5.6%	9,300	+10.7%	58.1%	16,000	500	24,400	7.5%	31,100	7.2%
	Mobic (antiflash agent)	8,600	10,600	24.7%	5,400	0.0%	3,200	0.0%	57.1%	5,600	0	8,600	0.0%	11,000	3.8%
	Miltax (anti-inflammatory analgesics)	4,800	6,000	1.7%	2,900	-6.5%	1,600	-5.9%	61.5%	2,600	0	4,500	-6.3%	5,500	-8.3%
Others	Omnipaque (non-ionic contrast agent)	28,200	34,700	1.5%	16,400	-8.9%	9,800	-3.9%	64.5%	15,200	1,000	26,200	-7.1%	31,600	-8.9%
	Kremezin (treatment for chronic renal failure)	10,400	13,000	-4.4%	6,000	-9.1%	3,500	-7.9%	54.7%	6,400	0	9,500	-8.7%	12,400	-4.6%
	Zantac (peptic ulcer therapeutic substance)	6,000	7,400	-12.9%	3,200	-17.9%	1,800	-14.3%	62.1%	2,900	0	5,000	-16.7%	6,100	-17.6%
	Omniscan (contrast medium for MRI)	4,400	5,400	5.9%	2,700	-3.6%	1,600	0.0%	64.0%	2,500	0	4,300	-2.3%	5,200	-3.7%
	Evoxac (agent for the treatment of dry-mouth)	1,100	1,300	8.3%	700	0.0%	400	0.0%	57.1%	700	0	1,100	0.0%	1,400	7.7%

### Export sales of main products

million yen

		FY2005			FY2006										
		1-3Q	Full Year	Change VS 2004	1st half		3Q		2nd half New Estimate		1-3Q		Full Year New Estimate		
					Change VS 2005	Progress	Change VS 2005	Progress	Difference from estimate	Change VS 2005	Change VS 2005				
	Pravastatin (antihyperlipidemic agent)	54,000	64,500	-16.2%	14,800	-61.7%	3,500	-77.3%	62.5%	5,600	-1,700	18,300	-66.1%	20,400	-68.4%
	Levofloxacin (oral antibacterial agent)	23,000	29,500	21.9%	16,400	10.1%	8,700	7.4%	54.0%	16,100	1,200	25,100	9.1%	32,500	10.2%

### Sales of main healthcare products

million yen

		FY2005			FY2006										
		1-3Q	Full Year	Change VS 2004	1st half		3Q		2nd half New Estimate		1-3Q		Full Year New Estimate		
					Change VS 2005	Progress	Change VS 2005	Progress	Difference from estimate	Change VS 2005	Change VS 2005				
	<b>Total sales of the Healthcare Segment</b>	<b>22,400</b>	<b>27,900</b>	<b>-5.7%</b>	<b>24,600</b>	<b>—</b>	<b>15,100</b>	<b>—</b>	<b>61.9%</b>	<b>24,400</b>	<b>-700</b>	<b>39,700</b>	<b>—</b>	<b>48,900</b>	<b>—</b>
	LuLu series	8,000	9,400	9.3%	5,300	12.9%	3,500	8.6%	70.0%	5,000	-400	8,800	10.0%	10,300	9.6%
	Shin-sankyo Ichoyaku series	2,600	3,300	10.0%	1,400	4.2%	900	-4.2%	60.0%	1,500	0	2,300	-11.5%	2,900	1.5%
	Karoyan series	1,700	2,100	-44.7%	1,200	3.1%	700	0.5%	70.0%	1,000	0	1,900	11.8%	2,200	6.4%
	Regain series	2,000	2,390	1.7%	1,200	-21.4%	500	-17.5%	55.6%	900	0	1,700	-15.0%	2,100	-12.1%
	Patecs series	1,600	2,000	-4.8%	1,100	1.7%	500	-10.5%	45.5%	1,100	0	1,600	0.0%	2,200	11.5%
	Lamisil AT	1,200	2,600	23.8%	1,100	-7.1%	—	—	—	—	—	1,100	—	—	—
	Gaster 10	—	—	—	1,800	—	1,300	—	61.9%	2,100	-100	3,100	—	3,900	—
	Precol	—	—	—	1,000	—	700	—	58.3%	1,200	-200	1,700	—	2,200	—
	Cakonal	—	—	—	800	—	700	—	63.6%	1,100	-200	1,500	—	1,900	—
	Makiron	—	—	—	1,100	—	300	—	50.0%	600	0	1,400	—	1,700	—

## 9.Sales of Overseas Subsidiaries

### U.S. subsidiaries—sales of main products

million yen

	FY2005				FY2006										
	1-3Q	Full Year			1st half	3Q			2nd half New Estimate	1-3Q	Full Year New Estimate				
				Change VS 2004		Change VS 2005	Progress	Difference from estimate			Change VS 2005	Change VS 2005			
<b>DAIICHI SANKYO INC. (DSI)</b>															
Benicar (antihypertensive) (\$ million)	36,200 (336)	50,300 (456)	66.0% 62.9%	53,300 (460)	133.8% 114.0%	19,700 (167)	47.0% 38.0%	50.1% 49.4%	<b>39,300</b> <b>(338)</b>	3,200 (25)	<b>73,000</b> <b>(627)</b>	101.7% 86.6%	<b>92,600</b> <b>(798)</b>	84.1% 75.0%	
WelChol (antihyperlipidemic agent) (\$ million)	11,000 (102)	14,800 (134)	17.5% 15.5%	13,100 (113)	77.0% 63.8%	4,800 (41)	33.3% 24.2%	49.0% 48.2%	<b>9,800</b> <b>(85)</b>	1,200 (10)	<b>17,900</b> <b>(154)</b>	62.7% 51.0%	<b>22,900</b> <b>(198)</b>	54.7% 47.8%	
Floxin Otic* (oral antibacterial agent) (\$ million)	6,000 (53)	8,100 (71)	6.6% 0.0%	4,500 (39)	40.1% 32.6%	1,700 (14)	66.6% 71.2%	51.5% 50.0%	<b>3,300</b> <b>(28)</b>	0 0	<b>6,200</b> <b>(53)</b>	46.7% 41.4%	<b>7,800</b> <b>(67)</b>	26.5% 24.1%	
Evoxac* (agent for the treatment of dry-mouth) (\$ million)	2,000 (18)	2,800 (25)	21.7% 13.6%	1,300 (11)	34.2% 26.9%	800 (7)	42.5% 30.6%	57.1% 58.3%	<b>1,400</b> <b>(12)</b>	0 0	<b>2,100</b> <b>(18)</b>	37.4% 28.3%	<b>2,700</b> <b>(23)</b>	12.3% 9.5%	
<b>Luitpold Pharmaceuticals, Inc. (LPI)</b>															
Venover (treatment for iron deficiency anemia) (\$ million)	15,800 (146)	22,600 (205)	16.5% 13.9%	20,600 (178)	100.0% 83.5%	8,500 (72)	54.5% 46.9%	60.3% 59.5%	<b>14,100</b> <b>(121)</b>	1,000 (8)	<b>29,100</b> <b>(250)</b>	84.2% 71.2%	<b>34,700</b> <b>(299)</b>	53.5% 45.9%	

\* Changed to net sales in FY2006. The year-on-year change for FY06 has been calculated by converting the sales in the previous year (net sales) to net sales.

The above figures for Benicar, WelChol and Venover are nine-month totals (January 2006–September 2006). Reference: Three months sales, Benicar ¥15,600 million (\$135 million); WelChol ¥3,900 million (\$33 million); Venover ¥6,800 million (\$57 million).

### European subsidiaries—sales of main products

million yen

	FY2005				FY2006										
	1-3Q	Full Year			1st half	3Q			2nd half New Estimate	1-3Q	Full Year New Estimate				
				Change VS 2004		Change VS 2005	Progress	Difference from estimate			Change VS 2005	Change VS 2005			
<b>DAIICHI SANKYO EUROPE GmbH (DSE)</b>															
Olmotec (antihypertensive) (€ million)	10,700 (79)	14,700 (107)	153.4% 148.8%	10,100 (71)	40.3% 34.0%	5,700 (38)	62.9% 46.2%	46.0% 44.2%	<b>12,400</b> <b>(86)</b>	0 0	<b>15,800</b> <b>(109)</b>	47.7% 38.0%	<b>22,500</b> <b>(157)</b>	53.1% 46.7%	
Mevalotin (antihyperlipidemic agent) (€ million)	3,800 (28)	5,500 (40)	-47.1% -48.7%	3,300 (23)	37.5% 27.8%	1,400 (9)	0.0% -10.0%	56.0% 47.4%	<b>2,500</b> <b>(19)</b>	0 0	<b>4,700</b> <b>(32)</b>	23.7% 14.3%	<b>5,800</b> <b>(42)</b>	5.5% 5.0%	